MEI Pharma (LSE:0JW9) - Stock Price, News & Analysis

0JW9 Stock Overview

A clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. More details

0JW9 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Shares are highly illiquid

Does not have a meaningful market cap ($19M)

MEI Pharma, Inc. Competitors

Hemogenyx Pharmaceuticals

LSE:HEMO

UK£20.5m

ProBiotix Health

OFEX:PBX

UK£10.7m

Synairgen

AIM:SNG

UK£9.3m

Verici Dx

AIM:VRCI

UK£8.2m

Price History & Performance

Summary of all time highs, changes and price drops for MEI Pharma
Historical stock prices
Current Share Price	US$2.80
52 Week High	US$6.83
52 Week Low	US$2.67
Beta	0.71
11 Month Change	2.16%
3 Month Change	-10.77%
1 Year Change	-52.26%
33 Year Change	-95.36%
5 Year Change	n/a
Change since IPO	-93.67%

Recent updates

Shareholder Returns

	0JW9	GB Biotechs	GB Market
7D	-3.4%	-5.2%	0.8%
1Y	-52.3%	-20.1%	6.6%

Return vs Industry: 0JW9 underperformed the UK Biotechs industry which returned -18.9% over the past year.

Return vs Market: 0JW9 underperformed the UK Market which returned 6.1% over the past year.

Price Volatility

Is 0JW9's price volatile compared to industry and market?
0JW9 volatility
0JW9 Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0JW9's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0JW9's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2000	28	Jay File	meipharma.com

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012.

MEI Pharma, Inc. Fundamentals Summary

How do MEI Pharma's earnings and revenue compare to its market cap?
0JW9 fundamental statistics
Market cap	US$18.72m
Earnings (TTM)	-US$46.60m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Is 0JW9 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JW9 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$14.38m
Gross Profit	-US$14.38m
Other Expenses	US$32.23m
Earnings	-US$46.60m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-6.99
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 0JW9 perform over the long term?

See historical performance and comparison

0JW9 Stock Overview

Risk Analysis

MEI Pharma, Inc. Competitors

LSE:HEMO

UK£20.5m

OFEX:PBX

UK£10.7m

AIM:SNG

UK£9.3m

AIM:VRCI

UK£8.2m

Price History & Performance

Recent News & Updates

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

Recent updates

MEI Pharma, Inc. Announces Management Changes

MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data

MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia

MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million.

MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023

MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023

MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023

MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023

MEI Pharma, Inc. Announces Board Changes

MEI Pharma, Inc. to Report Fiscal Year 2023 Results on Sep 26, 2023

MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN) in Patients with Previously Treated Metastatic Colorectal Cancer

MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023

MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023

MEI Pharma, Inc. Announces Executive Changes

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million.

MEI Pharma, Inc Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

Third quarter 2023 earnings released: US$2.32 loss per share (vs US$1.31 loss in 3Q 2022)

Insufficient new directors

Insufficient new directors

MEI Pharma, Inc. Initiates Realignment of Its Clinical Development Efforts

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

MEI Pharma, Inc. Announces Not Stand for Re-Election of Directors

MEI Pharma, Inc., Annual General Meeting, Dec 06, 2022

MEI Pharma, Inc. Announces Not Stand for Re-Election of Cheryl L. Cohen as Member of the Board of Directors

Mei Pharma Announces Changes to Board of Directors

MEI Pharma, Inc. Announces Board Changes

Full year 2022 earnings released: US$0.44 loss per share (vs US$0.37 loss in FY 2021)

MEI Pharma, Inc. to Report Fiscal Year 2022 Results on Sep 08, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma, Inc. announced delayed 10-Q filing

MEI Pharma Receives Non-Compliance Notice from Nasdaq

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

MEI Pharma, Inc. Announces New Key Executive Appointments

No longer forecast to breakeven

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

Independent Non Executive Director Kevan Clemens has left the company

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.019 loss in 1Q 2021)

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Full year 2021 earnings released: US$0.45 loss per share (vs US$0.51 loss in FY 2020)

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce First Patient Dosed in the Phase 3 Coastal Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-Cell Lymphoma

Forecast to breakeven in 2024

Forecast to breakeven in 2024

MEI Pharma, Inc.(NasdaqCM:MEIP) dropped from Russell 3000E Value Index

MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program

MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma, Inc. and Kyowa Kirin Announce New Clinical Data on Zandelisib At American Society of Clinical Oncology Annual Meeting 2021

MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress

Third quarter 2021 earnings released: US$0.28 loss per share (vs US$0.041 loss in 3Q 2020)

Independent Non-Executive Director recently sold US$101k worth of stock

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.26 loss in 2Q 2020)

Revenue beats expectations

MEI Pharma, Inc. Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update

Shareholder Returns

Price Volatility